MA44560B2 - Anticorps anti-cd38 spécifiques pour le traitement de cancers humains - Google Patents

Anticorps anti-cd38 spécifiques pour le traitement de cancers humains

Info

Publication number
MA44560B2
MA44560B2 MA44560A MA44560A MA44560B2 MA 44560 B2 MA44560 B2 MA 44560B2 MA 44560 A MA44560 A MA 44560A MA 44560 A MA44560 A MA 44560A MA 44560 B2 MA44560 B2 MA 44560B2
Authority
MA
Morocco
Prior art keywords
antibody
medicament
treatment
antibodies specific
human cancers
Prior art date
Application number
MA44560A
Other languages
English (en)
Other versions
MA44560B1 (fr
MA44560A1 (fr
Inventor
Antoine Deslandes
Krzysztof Grzegorzewski
Marie-Laure Ozoux
Blake Tomkinson
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA44560A1 publication Critical patent/MA44560A1/fr
Publication of MA44560B1 publication Critical patent/MA44560B1/fr
Publication of MA44560B2 publication Critical patent/MA44560B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un anticorps qui se lie spécifiquement à cd38 qui est capable de tuer une cellule cd38+ par induction de l'apoptose, d'une cytotoxicité à médiation cellulaire dépendant des anticorps (adcc) et d'une cytotoxicité dépendant du complément. L'anticorps divulgué peut être utilisé comme médicament ou dans la préparation d'un médicament, l'anticorps étant à administrer à un sujet humain à une dose thérapeutique sûre d'environ 20 mg/kg ou inférieure. Dans un mode de réalisation, le médicament est destiné à traiter le myélome multiple à cd38+ chez des êtres humains.
MA44560A 2014-07-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains MA44560B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306220 2014-07-31
PCT/US2014/063380 WO2015066450A1 (fr) 2013-10-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains

Publications (3)

Publication Number Publication Date
MA44560A1 MA44560A1 (fr) 2019-09-30
MA44560B1 MA44560B1 (fr) 2020-06-30
MA44560B2 true MA44560B2 (fr) 2021-01-29

Family

ID=51266255

Family Applications (2)

Application Number Title Priority Date Filing Date
MA39070A MA39070A1 (fr) 2014-07-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
MA44560A MA44560B2 (fr) 2014-07-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA39070A MA39070A1 (fr) 2014-07-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains

Country Status (20)

Country Link
US (2) US20150118251A1 (fr)
EP (2) EP3805266A1 (fr)
JP (2) JP2016536314A (fr)
KR (1) KR20160077155A (fr)
CN (1) CN106103481A (fr)
AU (1) AU2014342103B2 (fr)
BR (1) BR112016009403A2 (fr)
CA (1) CA2927099A1 (fr)
CR (1) CR20160186A (fr)
EA (1) EA035098B1 (fr)
IL (1) IL245196B (fr)
MA (2) MA39070A1 (fr)
MX (1) MX2016005666A (fr)
NZ (1) NZ719784A (fr)
PL (1) PL3063173T3 (fr)
PT (1) PT3063173T (fr)
SG (2) SG10201803288RA (fr)
TN (1) TN2016000142A1 (fr)
TW (1) TW201522378A (fr)
WO (1) WO2015066450A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
IL241407B (en) * 2013-03-13 2022-06-01 Univ California Preparations containing antibodies against cd-38 and carfilzomib
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016040294A2 (fr) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-cd38
NZ732753A (en) 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
HUE054271T2 (hu) * 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
KR102602754B1 (ko) * 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
WO2016201337A1 (fr) * 2015-06-12 2016-12-15 Immungene, Inc. Molécules de fusion d'interféron et d'anticorps obtenues par génie génétique pour le traitement de cancers exprimant la protéine 94 régulée par le glucose (grp94)
ES2890783T3 (es) 2015-06-22 2022-01-24 Janssen Biotech Inc Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-CD38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN108472369A (zh) * 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3016098A1 (fr) 2016-03-04 2017-09-08 Morphosys Ag Evaluation clinique de reponse de proteine m dans le myelome multiple
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
CR20220408A (es) 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Antibodies against BCMA containing only heavy chains and their uses
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
EP3667318A4 (fr) * 2017-08-07 2021-05-26 Kyushu University, National University Corporation Procédé de mesure du taux d'occupation de substances de liaison spécifiques dans une population cellulaire
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
WO2019055689A1 (fr) * 2017-09-13 2019-03-21 Teneobio, Inc. Anticorps à chaîne lourde se liant à des exoenzymes
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
EP3704156A1 (fr) 2017-11-03 2020-09-09 Sorrento Therapeutics, Inc. Constructions de récepteur antigénique chimérique dirigé contre cd38
US20210047427A1 (en) * 2018-03-28 2021-02-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
TW202019962A (zh) * 2018-07-10 2020-06-01 法商賽諾菲公司 標靶CD38及TGF-β的組合療法
WO2020120730A1 (fr) 2018-12-14 2020-06-18 Morphosys Ag Formulations d'anticorps
IL286482B1 (en) * 2019-03-21 2024-09-01 Gamida Cell Ltd NK cell segments from culture for use in combination therapy
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CA3140816A1 (fr) 2019-06-14 2020-12-17 Nathan Trinklein Anticorps a chaines lourdes multispecifiques se liant a cd22 et cd3
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
US20210188996A1 (en) 2019-12-05 2021-06-24 Sanofi-Aventis U.S. Llc Formulations of anti-cd38 antibodies for subcutaneous administration
EP4069740A1 (fr) * 2019-12-06 2022-10-12 Sanofi-Aventis U.S. LLC Utilisation d'isatuximab pour le traitement d'un myélome multiple réfractaire et/ou récidivant
KR20230027270A (ko) * 2020-06-23 2023-02-27 지앙수 카니온 파마수티컬 씨오., 엘티디. 항-cd38 항체 및 그의 용도
WO2022117572A2 (fr) 2020-12-02 2022-06-09 Oncurious Nv Agoniste de ltbr utilisé pour la polythérapie contre le cancer
WO2024094660A1 (fr) * 2022-10-31 2024-05-10 Genmab A/S Anticorps cd38 et leurs utilisations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
WO1998046645A2 (fr) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Nouveau procede de production de recepteurs d'anti-antigenes humains et leur utilisation
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1976950B (zh) * 2004-02-06 2012-08-29 莫佛塞斯公司 抗cd38人抗体及其用途
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US20090123950A1 (en) * 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
PL2081595T3 (pl) * 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
EP2191841A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
EP2191842A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
EP2191843A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
EP2191840A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SG11201401518TA (en) * 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
IL241407B (en) * 2013-03-13 2022-06-01 Univ California Preparations containing antibodies against cd-38 and carfilzomib

Also Published As

Publication number Publication date
IL245196A0 (en) 2016-06-30
IL245196B (en) 2021-04-29
US20150118251A1 (en) 2015-04-30
EP3063173A1 (fr) 2016-09-07
CN106103481A (zh) 2016-11-09
EA035098B1 (ru) 2020-04-27
EP3805266A1 (fr) 2021-04-14
JP2023109927A (ja) 2023-08-08
WO2015066450A1 (fr) 2015-05-07
US20180022814A1 (en) 2018-01-25
EA201690905A1 (ru) 2016-08-31
NZ719784A (en) 2022-02-25
EP3063173B1 (fr) 2020-07-29
AU2014342103B2 (en) 2020-06-04
TN2016000142A1 (en) 2017-10-06
PL3063173T3 (pl) 2021-01-11
SG10201803288RA (en) 2018-05-30
SG11201603088RA (en) 2016-05-30
JP2016536314A (ja) 2016-11-24
MX2016005666A (es) 2016-07-14
AU2014342103A1 (en) 2016-05-26
PT3063173T (pt) 2020-10-20
MA44560B1 (fr) 2020-06-30
TW201522378A (zh) 2015-06-16
CA2927099A1 (fr) 2015-05-07
MA44560A1 (fr) 2019-09-30
CR20160186A (es) 2016-06-13
KR20160077155A (ko) 2016-07-01
BR112016009403A2 (pt) 2017-09-19
MA39070A1 (fr) 2017-11-30

Similar Documents

Publication Publication Date Title
MA44560A1 (fr) Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
JP2016536314A5 (fr)
JP2017507954A5 (fr)
EA201691747A1 (ru) Варианты комбинированной терапии с антителами анти-cd38
JP2018516969A5 (fr)
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
MY191423A (en) Binding molecules specific for cd73 and uses thereof
EA201892541A1 (ru) Гуманизированные анти-il-1r3 антитела
MX348581B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
CA2939464A1 (fr) Utilisation d'anticorps anti-ccr5 dans la maladie du greffon contre l'hote
EP3991749A3 (fr) Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps
MX2017014396A (es) Tratamiento de mieloma multiple.
EA201370162A1 (ru) Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
JP2017537927A5 (fr)
JP2019533682A5 (fr)
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers